Skip to main
CLGN

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies is a company with strong partnerships and continued expansion, both in terms of its distribution infrastructure and its product offerings. While there are some risks involved, such as regulatory and financial risks, the company's innovative technology and increasing scientific validation make it a strong contender in the 3D bioprinting and medical aesthetics market. There is potential for further growth and success, but investors should consider the company's reliance on external financing and the possibility of dilution in the future.

Bears say

CollPlant Biotechnologies is facing challenges in the current capital environment and has recently experienced a disproportionately negative reaction in the stock due to a modest capital raise. While the company continues to advance its commercial programs and development pipeline, the success of its dermal filler partnership with AbbVie and potential contributions from its new logistics center will be key catalysts for market outlook and cashflow. The company's valuation, based on its rhCollagen technology platform in aesthetics and 3D bioprinting for breast implants, is highly dependent on assumptions and future capital raises, leading to a uncertain outlook.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.